

(12) **United States Patent**  
Kurimoto et al.

(10) **Patent No.:** US 8,012,964 B2  
(45) **Date of Patent:** Sep. 6, 2011

(54) **9-SUBSTITUTED 8-OXOADENINE  
COMPOUND**

(75) Inventors: **Ayumu Kurimoto**, Osaka (JP); **Yoshiaki Isobe**, Osaka (JP); **Stephen Brough**, Loughborough (GB); **Hiroki Wada**, Loughborough (GB); **Roger Bonnert**, Loughborough (GB); **Thomas McNally**, Loughborough (GB)

(73) Assignees: **Dainippon Sumitomo Pharma Co., Ltd.**, Osaka-Shi, Osaka (JP); **Astrazeneca Aktiebolag**, Soedertaelje (SE)

(\*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 512 days.

(21) Appl. No.: **10/593,691**

(22) PCT Filed: **Mar. 24, 2005**

(86) PCT No.: **PCT/JP2005/005401**

§ 371 (c)(1),

(2), (4) Date: **Dec. 4, 2006**

(87) PCT Pub. No.: **WO2005/092893**

PCT Pub. Date: **Oct. 6, 2005**

(65) **Prior Publication Data**

US 2007/0190071 A1 Aug. 16, 2007

(30) **Foreign Application Priority Data**

Mar. 26, 2004 (JP) ..... 2004-093672

(51) **Int. Cl.**

**C07D 473/18** (2006.01)

**A61K 31/522** (2006.01)

**A61P 37/06** (2006.01)

**A61P 37/08** (2006.01)

**A61P 11/06** (2006.01)

(52) **U.S. Cl.** ..... **514/234.2**; 544/118; 544/276; 544/277

(58) **Field of Classification Search** ..... 544/118, 544/276, 277, 234.2; 514/234.2, 263.22, 514/263.23, 263.37, 118

See application file for complete search history.

(56) **References Cited**

**U.S. PATENT DOCUMENTS**

4,689,338 A 8/1987 Gerster  
4,698,348 A 10/1987 Gerster  
4,714,701 A 12/1987 Beauchamp  
5,736,549 A 4/1998 Beasley et al.  
5,994,361 A 11/1999 Penney et al.  
6,028,076 A 2/2000 Hirota et al.  
6,110,923 A 8/2000 Ely  
6,329,381 B1 12/2001 Kurimoto et al.  
6,376,501 B1 4/2002 Isobe et al.  
6,458,798 B1 10/2002 Fujita et al.  
6,630,478 B2 \* 10/2003 Diamond et al. .... 514/263.35

6,951,866 B2 10/2005 Fujita et al.  
7,157,465 B2 1/2007 Isobe et al.  
7,521,454 B2 4/2009 Isobe et al.  
7,642,350 B2 \* 1/2010 Pryde ..... 544/61  
2002/0040032 A1 \* 4/2002 Glasky et al. .... 514/263.35  
2002/0068745 A1 6/2002 Levy et al.  
2002/0128264 A1 9/2002 Taylor  
2003/0105323 A1 6/2003 Fujita et al.  
2003/0144283 A1 7/2003 Coleman et al.  
2003/0191086 A1 10/2003 Hanus et al.  
2003/0212092 A1 11/2003 Heppner et al.  
2004/0019048 A1 1/2004 Crooks et al.  
2004/0132748 A1 7/2004 Isobe et al.  
2004/0204438 A1 10/2004 Crooks et al.  
2004/0229897 A1 11/2004 Crooks et al.  
2005/0054590 A1 3/2005 Averett

(Continued)

**FOREIGN PATENT DOCUMENTS**

CA 1220148 A1 4/1987

(Continued)

**OTHER PUBLICATIONS**

Dvorakova, Journal of Medicinal Chemistry (1996), 39(17), 3263-3268.\*


(Continued)

Primary Examiner — Mark L Berch

(74) Attorney, Agent, or Firm — Birch, Stewart, Kolasch & Birch, LLP

(57) **ABSTRACT**

The present invention provides an 8-oxoadenine compound having immunomodulating activities such as an interferon inducing activity and useful as an antiviral agent and anti-allergic agent, which is represented by the following formula (1):



[wherein the ring A represents a 6-10 membered aromatic carbocyclic ring and the like, R represents a halogen atom, an alkyl group and the like, n represents an integer of 0-2, Z<sup>1</sup> represents alkylene, X<sup>2</sup> represents oxygen atom, sulfur atom, SO<sub>2</sub>, NR<sup>5</sup>, CO, CONR<sup>5</sup>, NR<sup>5</sup>CO and the like, Y<sup>1</sup>, Y<sup>2</sup> and Y<sup>3</sup> represent independently a single bond or an alkylene group, X<sup>1</sup> represents oxygen atom, sulfur atom, NR<sup>4</sup> (R<sup>4</sup> is hydrogen atom or an alkyl group) or a single bond, R<sup>2</sup> represents a substituted or unsubstituted alkyl group, R<sup>1</sup> represents hydrogen atom, hydroxy group, an alkoxy group, an alkoxy carbonyl group or a haloalkyl group] or its pharmaceutically acceptable salt.

**4 Claims, No Drawings**